SEGMENT AND GEOGRAPHIC AREA INFORMATION (Tables)

12 Months Ended

Sep. 30, 2022

SEGMENT AND GEOGRAPHIC AREA INFORMATION

Schedule of information regarding operations by segment

Information regarding operations by segment for the twelve- month period ended September 30, 2022 is as follows:

	Therapeutic DNA		MDx Testing		DNA Tagging and
	Production		Services		Security Products		Consolidated
Revenues:
Product revenues	$	—	$	628,286	$	1,254,518	$	1,882,804
Service revenues		439,355		—		319,783		759,138
Clinical laboratory service revenues		—		15,979,631		—		15,979,631
Less intersegment revenues		—		(452,896)		—		(452,896)
Total revenues		439,355		16,155,021		1,574,301		18,168,677
Gross profit		439,355		4,827,672		(213,387)		5,053,640
Loss from segment operations (a)		(4,497,699)		(464,894)		(4,652,786)		(9,615,379)

Information regarding operations by segment for the twelve- month period ended September 30, 2021 is as follows:

	Therapeutic DNA		MDx Testing		DNA Tagging and
	Production		Services		Security Products		Consolidated
Revenues:
Product revenues	$	—	$	1,943,697	$	1,352,152	$	3,295,849
Service revenues		559,319		—		378,416		937,735
Clinical laboratory service revenues		—		5,090,794		—		5,090,794
Less intersegment revenues		—		(296,640)		—		(296,640)
Total revenues		559,319		6,737,851		1,730,568		9,027,738
Gross profit		559,318		3,327,080		596,508		4,482,906
Loss from segment operations (a)		(5,214,221)		(274,250)		(4,823,348)		(10,311,819)

(a) Segment operating loss consists of net sales less cost of sales, specifically identifiable research and development, and selling, general and administrative expenses.

Schedule of reconciliation of segment loss from operations to corporate loss

	2022		2021
Loss from operations of reportable segments	$	(9,615,379)	$	(10,311,819)
General corporate expenses (b)		(4,354,384)		(3,036,822)
Interest income (expense), net		7,200		13,675
Unrealized gain on change in fair value of warrants		17,999,521		—
Transaction costs related to warrant liabilities		(1,668,112)		—
Loss on issuance of warrants		(10,591,600)		—
Loss on extinguishment of convertible notes payable		—		(1,774,662)
Gain on extinguishment of notes payable		—		839,945
Other expense, net		(47,305)		(8,756)
Consolidated loss before provision for income taxes	$	(8,270,059)	$	(14,278,439)

(b) General corporate expenses consists of Selling, general and administrative expenses that are not specifically identifiable to a segment.

Schedule of net revenues by geographic location of customers

	Year Ended September 30,
	2022		2021
Americas	$	17,544,444	$	8,520,336
Europe		448,847		359,509
Asia and other		175,386		147,893
Total	$	18,168,677	$	9,027,738